Nometex is a non-drug treatment that uses NMT’s proprietary neuromodulation technology platform to modulate neural pathways using electrical pulses for prophylaxis, breakthrough, or refractory CINV.
Neurowave said the clinical study conducted to test the efficacy of Nometex in gynecologic oncology patients resulted in a reduction in the severity of nausea over days 2-4.
The first model Nometex N2C will provide up to 150 hours of therapy which can help patients through two cycles of therapy and the associated CINV episodes.
Neurowave Medical Technologies Marketing vice president Chris Littel said Nometex represents a new therapeutic direction that puts patients in control of managing acute and delayed CINV syndromes through 2-3 cycles of chemotherapy.
